---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-010419"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T14:22:18.083917+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Enveric signs non-binding term sheets for out-licensing joint disease compounds; up to $82M in milestones

## Summary
- Two non-binding term sheets with undisclosed biotech to out-license cannabinoid-COX-2 conjugates for joint disease (osteoarthritis, rheumatoid arthritis).
- Pharma license potential milestones up to ~$61M; non-pharma up to ~$21M; combined up to ~$82M.
- Royalty rates: pharma 2.5%-10%, non-pharma 0.25%-7% on future sales; licensee funds all development.
- CEO Joseph Tucker highlights second company to license Enveric assets; definitive agreements remain to be negotiated.
- Enveric focuses on neuroplastogenic therapeutics; out-licensing diversifies revenue from its asset portfolio.

## SEC filing metadata
- accession: 0001493152-24-010419
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315224010419/0001493152-24-010419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315224010419/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-010419
- JSON: https://secwatch.observer/filing/0001493152-24-010419.json
- Plain text: https://secwatch.observer/filing/0001493152-24-010419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.